Galapagos NV Investor Relations Material
Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises four Phase 2 programs, three Phase 1 trials, five pre-clinical studies, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis, and other indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium
Upcoming events for
Q3 20222022-11-04
Q2 20222022-08-05
Latest company events
Ticker symbol
GLPG
Country
Netherlands
About the company
Investor Relations Page
Dig deeper into the Galapagos NV fundamentals on Quartr.
- Skip straight to the Q&A session
- Receive notifications about new events
- Connect the financial calender on your phone
- Figure out why the stock is up or down
- Read the transcripts or scroll the deck
- Access earnings or press releases
